This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Queen's University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $1,575,898
Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial
CIHR · 2026 · Co-investigator
- $761,175
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial
CIHR · 2022 · Principal investigator
Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial
Principal investigators: Parulekar, Wendy R; Ethier, Josee-Lyne
Keywords: Endocrine Therapy; Endometrial Cancer; International; Molecular Classification; Non-Inferiority; Phase Iii; Quality Of Life; Radiotherapy; Randomized
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial
Principal investigators: Parulekar, Wendy R; Welch, Stephen A
Keywords: Adjuvant Therapy; Endometrial Cancer; Immunotherapy; Mismatch Repair Deficiency; Molecular Classification; Personalized Medicine; Predictive Biomarkers; Quality Of Life; Randomized Phase Iii Trial
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.